Exercise may fight fatty liver by targeting hidden muscle fat
NCT ID NCT06506513
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial investigates whether different intensities of physical exercise can reduce fat stored in muscles (myosteatosis) and improve liver health in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will compare high-intensity interval training, moderate intensity exercise, and low intensity exercise over several weeks. The goal is to see if reducing muscle fat can help treat the liver condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- exercise training (high-intensity interval training, moderate intensity, or low intensity)
- What this could lead to
- If successful, this could show that tailored exercise programs are an effective way to treat fatty liver disease by targeting muscle fat.
- What could go wrong
- This is a small, early-stage trial with 60 participants, so results may not apply to everyone. It is also unclear which exercise intensity works best or if benefits last long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * confirmed MASLD at abdominal imaging * confirmed excessive muscle lipid content at imaging * stable weight Exclusion Criteria: * severe comorbidities including active malignancies, neuromuscular degenerative diseases * contraindications to physical activity * excessive alcohol consumption
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatotic liver disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre d'investigation clinique en nutrition
RECRUITINGLouvain-la-Neuve, 1348, Belgium
-
Cliniques universitaires Saint-Luc
RECRUITINGBrussels, 1200, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Can exercise melt away liver fat?
- A blood test for liver trouble may flag hidden risk in sleep apnea patients
- Thyroid trouble may worsen liver scarring in fatty liver disease
- Can liver scarring predict heart trouble?
- Can a diabetes drug combo revive the Body's growth hormone axis and protect the liver?